NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 3 words
- Enrollment increased: 1750 → 2250 participants
- Study sites: 266 to 267
- Minor Study sites: 265 to 266
- Notable Eligibility criteria shortened, about 4 words
- Trial sites expanded: 251 → 265 locations
- Secondary endpoints: details revised at 1 of 4 entries
- Minor Trial sites expanded: 240 → 251 locationsv14
- Minor Enrollment increased: 1250 → 1750 participants
- Trial sites expanded: 233 → 240 locations
- Eligibility criteria revised
- Minor Trial sites expanded: 223 → 233 locationsv12
- Minor Trial sites expanded: 207 → 223 locationsv11
- Minor Trial sites expanded: 157 → 207 locationsv10
- Minor Study sites: 59 to 157v8
- Minor Study sites: 36 to 59v7
- Minor Study sites: 17 to 36v6
- Minor Study sites: 6 to 17v5
- Minor Study sites: 3 to 6v4
- Minor Study sites: 2 to 3v3
- Notable Eligibility criteria expanded, about 11 words
- Start date changed from estimate of Jul 1, 2025 to Jul 2, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Participants will receive placebo administered subcutaneously (SC) once every 6 months (q6M) during the double-blind (DB) period, followed by nucresiran 300 mg administered SC q6M during the open-label extension (OLE) period.
Participants will receive nucresiran 300 mg administered SC Q6M during the DB period, followed by nucresiran 300 mg administered SC q6M during the OLE period.
Drugs: Nucresiran, Sterile Normal Saline (0.9% NaCl)
Sites
267 sites in 36 countries
United States 45, China 22, Japan 18, Spain 18, France 16, Italy 15, Brazil 12, Belgium 11, Germany 11, Argentina 8, Australia 8, Austria 7, Portugal 7, United Kingdom 6, Netherlands 5, South Korea 5, Switzerland 5, Canada 4, Czechia 4, Greece 4, Israel 4, Taiwan 4, Denmark 3, New Zealand 3, Sweden 3, Turkey (Türkiye) 3, Chile 2, Hungary 2, Ireland 2, Malaysia 2, Norway 2, Romania 2, Hong Kong 1, Mexico 1, Poland 1, Slovakia 1